Comparative Pharmacology
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus INDERIDE 80 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus INDERIDE 80 25.
ACEBUTOLOL HYDROCHLORIDE vs INDERIDE-80/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker) with intrinsic sympathomimetic activity (ISA). Competitively blocks catecholamine binding at cardiac beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure. ISA provides mild beta-receptor stimulation, decreasing the extent of resting bradycardia and lipid changes.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Dose: 200-800 mg/day orally in 1-2 divided doses. Initially 200 mg twice daily; may increase to 400 mg twice daily as needed.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
None Documented
None Documented
3-4 hours for acebutolol; 8-13 hours for diacetolol (active metabolite); clinically significant in renal impairment
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Renal: 30-40% as unchanged drug and 50-60% as diacetolol; fecal: ~10%
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Category C
Category C
Beta Blocker
Beta Blocker and Thiazide Diuretic